Expertise in
18
conditions

Dr. Sherif S. Farag

Hematology
Community Howard Regional Health
3500 S Lafountain St, 
Kokomo, IN 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
36 Years of Experience
Expertise in
18
conditions
Community Howard Regional Health
3500 S Lafountain St, 
Kokomo, IN 

Overview

Sherif Farag is a Hematologist practicing medicine in Kokomo, Indiana. He has been practicing medicine for over 36 years.

Dr. Farag is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 9 clinical trials. Dr. Farag is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in IN

Hospital Affiliations

Community Howard Regional Health Inc.
Community Hospital North
Community Hospital Of Anderson And Madison County
Community Hospital South, Inc.
Community Hospital East

Languages Spoken

English
Arabic
Arabic - Jordanian

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Community Howard Regional Health
3500 S Lafountain St, Kokomo, IN 46902

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological
Study Phase: Phase 2
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 2
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 3
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Biological
Study Drug: Neihulizumab (AbGn-168H)
Study Phase: Phase 1
A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase II Trial of Inhibition of Dipeptidyl Peptidase (DPP)-4 With Sitagliptin for the Prevention of Acute Graft Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Phase II Trial of Inhibition of Dipeptidyl Peptidase (DPP)-4 With Sitagliptin for the Prevention of Acute Graft Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
Enrollment Status: Completed
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

53 Total Publications

Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study.
Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study.
Journal: Transplantation
Published: June 23, 2025
Similar Doctors
Expertise in
6
conditions
Dr. Amy D. Shapiro
Hematology | Oncology
Expertise in
6
conditions
Dr. Amy D. Shapiro
Hematology | Oncology
Referral may be required

Indiana Hemophilia And Thrombosis Center Inc

8326 Naab Rd, 
Indianapolis, IN 
 (37.5 miles away)
317-871-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amy Shapiro is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Shapiro is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Hemophilia B, and Ligneous Conjunctivitis. Dr. Shapiro is currently accepting new patients.

Expertise in
14
conditions
Dr. Brian D. Weiss
Hematology | Oncology
Expertise in
14
conditions
Dr. Brian D. Weiss
Hematology | Oncology
Referral may be required

Riley Hospital For Children At Indiana University Health

705 Riley Hospital Dr, 
Indianapolis, IN 
 (46.3 miles away)
317-944-2143
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brian Weiss is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Weiss is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Neurofibromatosis, Lithotripsy, and Bone Marrow Transplant. Dr. Weiss is currently accepting new patients.

Expertise in
29
conditions
Dr. Daniel A. Rushing
Hematology | Oncology
Expertise in
29
conditions
Dr. Daniel A. Rushing
Hematology | Oncology
Referral may be required

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (46.5 miles away)
317-948-8310
Languages Spoken:
English
See accepted insurances

Daniel Rushing is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Rushing is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, and Bone Tumor.

Frequently Asked Questions about Dr. Sherif S. Farag

How do I make an appointment with Dr. Sherif S. Farag?

You can book an appointment with Dr. Sherif S. Farag by calling their office at 765-776-3500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sherif S. Farag a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sherif S. Farag is classified as an Distinguished expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sherif S. Farag specialize in?

While Dr. Sherif S. Farag is a Hematology, they have specific expertise in Graft Versus Host Disease (GvHD), Multiple Myeloma, and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sherif S. Farag participate in research or clinical trials?

Yes. Dr. Sherif S. Farag has published 53 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Dr. Sherif S. Farag's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sherif S. Farag accept my insurance?

Dr. Sherif S. Farag accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 765-776-3500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Farag's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile